Eli Lilly Business Model Canvas

Eli Lilly outsources clinical operations, data management, and specialized manufacturing to CROs, CMOs and tech vendors, tapping a CRO market that exceeded $60 billion in 2024 to scale global trials rapidly. These partners provide flexible capacity and speed while advanced manufacturing and analytics platforms drive quality, scalability and cost-efficiency across production. Integrated digital tools (EHR-linked capture, cloud analytics, eCOA, eConsent) ensure real-time data, traceability and regulatory compliance.

Collaborate with academic and research centers for discovery and translational science, leveraging NIH ~49 billion USD budget in 2024 for grants.

Form strategic alliances and in‑licensing with biotechs, outsourcing to a CRO/CMO market >60 billion USD in 2024; Lilly reported $40.8B revenue in 2023.

Partner with regulators (FDA priority review ~6 months, EMA centralized ~210 days) and payers for value‑based contracts and access.

Eli Lilly manages global regulatory submissions and interactions with agencies including the FDA and EMA, coordinating filings and reviews throughout 2024. The company enforces GMP, GCP and GLP standards across manufacturing and clinical operations. Pharmacovigilance teams monitor safety signals and deploy risk mitigation plans. Lifecycle compliance processes ensure timely labeling updates and post‑approval commitments.

Identify targets and optimize leads via integrated biology/chemistry, advancing hundreds of programs and investing about $9B R&D in 2024 to de-risk pipeline. Execute Phase I–III and post‑marketing studies, real‑world evidence and KOL engagement to secure approvals and payer access. Scale manufacturing across small molecules, biologics and injectables with cold‑chain, CMOs and redundancy to protect supply.

Eli Lilly’s manufacturing network, comprising over 20 global plants and extensive CMO relationships, delivers scale and flexibility for supply continuity. Capabilities cover biologics, peptides and complex injectables, supported by advanced automation and rigorous quality systems to ensure batch-to-batch consistency. Recent multi-year capacity investments target high-demand launches and peak-volume supply needs in oncology and diabetes.

Experienced R&D teams and 2024 R&D spend of 8.6B USD sustain pipelines in oncology, diabetes, immunology. Global manufacturing (20+ plants) plus CMOs ensure supply for 2024 revenue 44.8B USD. Comprehensive clinical and real-world datasets, advanced analytics, and strong payer/HCP relationships drive commercialization.

Offer cost-effectiveness by reducing utilization and improving outcomes through value-based contracts and tiered pricing, mitigating the estimated US medication nonadherence cost of 100–300 billion USD annually. Structure outcomes-linked contracts and robust patient-support programs to lower total cost of care. Facilitate adherence via education, digital tools and nurse support. Enable broader access across payers and health systems.

Eli Lilly delivers first-in-class, disease-modifying therapies across diabetes, obesity, oncology, immunology, neuroscience and CV disease to improve outcomes and survival.

Pipeline emphasizes transformative mechanisms supported by rigorous clinical programs and peer-reviewed evidence to drive approvals and guideline shifts.

2024 R&D spend ≈ $8.1B and capex ≈ $6.5B underpin manufacturing quality, supply resilience and rapid scale-up.

Negotiate coverage, pricing and formulary access with major payers and HTAs, leveraging Eli Lilly’s 2024 commercial footprint (roughly $45.3B in annual revenues) to secure placement and rebates. Present health economic and outcomes research (HEOR) to demonstrate value and drive QALY-based decisions in HTA reviews. Explore outcomes-based and risk-sharing agreements tied to real-world endpoints. Maintain ongoing performance reviews and data-sharing to optimize access.

Eli Lilly builds long-term, data-driven partnerships with hospitals, payers and HCPs via outcomes-based contracts, HEOR, digital engagement and patient support programs; 2024 priorities: ~6,000 US hospitals, $9.2B R&D, $46.5B revenue, expanded copay/onboarding services.

Secure formulary placement and hospital/IDN protocols drive access for high-value Lilly products, leveraging a company market cap above $600B (2024) to negotiate placement. Lilly routes complex biologics through specialty pharmacies as specialty drugs account for about 60% of US drug spend (2023–24). Dedicated hub services streamline prior authorizations, cutting delays that cause ~20–30% treatment interruptions and improving adherence up to 15%.

Field reps, supported by medical affairs, drive adoption across specialty centers; Lilly reported ~$44B revenue and >$600B market cap in 2024. National wholesalers (McKesson, AmerisourceBergen, Cardinal) reach ~85–90% of U.S. pharmacies; specialty hubs cut 20–30% treatment interruptions and can boost adherence ~15%.

Payers and health systems including private insurers, PBMs (CVS Caremark, Express Scripts, OptumRx) and public payers (Medicare ~66 million enrollees in 2024) evaluate total cost of care and outcomes to drive formulary and access decisions. Employer and government formularies increasingly demand robust HEOR and RWE evidence; industry surveys report roughly 70–75% of payers use RWE in coverage decisions. Lilly must supply cost-offset and outcome data to secure access.

Specialists (endocrinology, oncology, immunology, neurology, cardiology) and primary care drive prescribing for chronic disease—~60% of US adults have ≥1 chronic condition (CDC 2024).

Hospitals/IDNs manage formularies and demand supply reliability; hospital care ~33% of US health spend (2024).

Payers (PBMs, Medicare ~66M enrollees 2024) require HEOR/RWE; ~70–75% use RWE in decisions (2024).

Patients/caregivers need effective, tolerable, accessible therapies; adherence to long‑term meds ~50% (WHO).

Field force and medical education remain central, with omnichannel content complementing face-to-face detailing; major biologic launches typically require field forces plus digital reach and launch investments often exceeding $1 billion to scale awareness and access.

Market research and launch spending drive segmentation and payer negotiation strategies, where formulary rebates and contracting tactics can shift net prices by 20–30% for high-cost specialty medicines.

Patient support programs and outcomes-based contracts (including co-pay assistance and hub services) plus post-launch evidence generation via registries and real‑world studies (often enrolling thousands) underpin reimbursement and uptake.

Eli Lilly 2024 cost structure: R&D ~$10.7B; manufacturing/COGS driven by complex biologics with scale efficiencies; launches often >$1B; rebates/contracting reduce net price 20–30% while patient support and compliance add significant OPEX.

Licensing and milestone payments give Eli Lilly upfronts, staged milestones and opt-in fees from partnered assets while out-licensing non-core technologies; these deals shift development risk and create risk-sharing monetization of the pipeline, diversifying cash flows and smoothing revenue volatility.

Core revenue from branded therapies; product sales >$40 billion in 2024, driven by GLP-1 and specialty biologics. High-margin injectables and lifecycle management sustain growth. Licensing, royalties and value-based contracts diversify cash flow and stabilize pricing under payor scrutiny.